408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer
Aung Naing(The University of Texas MD Anderson Cancer Center), Hirva Mamdani(Wayne State University), Sara Ferrando‐Martínez(National Institutes of Health), Jean Fan(Johns Hopkins University), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Richard D. Kim(Moffitt Cancer Center), Melissa L. Johnson(Tennessee Oncology), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Shubham Pant(The University of Texas MD Anderson Cancer Center), Dae Won Kim(Gangneung–Wonju National University), Byung Ha Lee(OncoImmune (United States)), Ngocdiep T. Le(GlaxoSmithKline (United States)), Minal Barve(Mary Crowley Cancer Research Center)
Cited by 4
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain
|Nature Biotechnology|2017|1.1k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835